Cybin Shareholders Weigh Helus Pharma Rebrand, Eight-Member Board

Key Points

• Cybin, doing business as Helus Pharma, asked shareholders to approve changing the corporate name to Helus Pharma Inc. and setting the board at eight directors; both resolutions required at least two-thirds approval.
• Shareholders considered appointing Zeifmans LLP as auditor and electing eight nominees, including Eric So, Michael Halstead, Paul Glavine, Theresa Firestone and Freda Lewis-Hall.
• Vote totals and final results were not announced during the meeting; the company said voting particulars would be published afterward.

Cybin NASDAQ: HELP, doing business as Helus Pharma, held its Annual General and Special Meeting of Shareholders, where shareholders were asked to consider resolutions related to the company’s auditor, board size, corporate name and director elections.

Eric So, the company’s co-founder and executive chairman, chaired the virtual meeting, which was hosted through Odyssey Trust Company’s shareholder meeting platform. So said the company had established quorum and that the meeting was properly constituted to conduct business.

The meeting materials, including the notice of meeting, management information circular, proxy form and financial statement request card, had been sent to shareholders of record as of Aug. 14, 2026, according to So. The company’s financial statements for the year ended March 31, 2026, along with the auditor’s report, were presented to shareholders. Copies are available through SEDAR+ and the company’s investor website, So said.

Auditor Appointment and Board Size

Shareholders were asked to appoint Zeifmans LLP as the company’s auditor and authorize the board to determine the auditor’s remuneration. Greg Cavers, Helus Pharma’s chief financial officer, moved the resolution, and director Paul Glavine seconded it.

The company also put forward a special resolution to set the number of directors at eight. The resolution required approval from at least two-thirds of the votes cast at the meeting. Cavers moved the measure and Glavine seconded it.

Proposed Name Change to Helus Pharma

Another special resolution sought shareholder approval to change the corporation’s name from Cybin Inc. to Helus Pharma Inc., or another name approved by the board and accepted by applicable regulatory authorities.

The name-change proposal also required support from at least two-thirds of the votes cast. Cavers moved the resolution, while Glavine seconded it.

Cybin had already been described throughout the meeting as doing business as Helus Pharma.

Director Nominees

Following the special resolutions, shareholders considered the election of directors. So said no director nominations beyond management’s nominees had been received in accordance with the company’s bylaws, and nominations from the floor would not be accepted.

Cavers nominated the following eight individuals for election to the board:

• Theresa Firestone
• Grant Froese
• Paul Glavine
• Michael Halstead
• Eric Hoskins
• Mark Lawson
• Freda Lewis-Hall
• Eric So

Glavine seconded the nominations. The meeting was attended by So, Chief Executive Officer Michael Halstead, Cavers and Glavine, among others involved in the meeting’s administration.

Voting was conducted through the virtual platform and by proxies received before the cutoff time. So said shareholders who had previously voted did not need to vote again, as a subsequent vote would revoke a prior submission.

The company did not announce vote totals or final results during the formal meeting. So said particulars of votes cast on each matter would be published by the corporation after the meeting and could also be obtained from the secretary.

After the voting period closed, shareholders approved a motion to conclude the meeting, formally ending the session.

About Cybin (NASDAQ:HELP)

Cybin Inc is a clinical-stage biopharmaceutical company focused on developing psychedelic-based therapeutics for the treatment of mental health conditions. The company combines drug discovery, clinical development and proprietary formulation technologies to design potentially more efficient and scalable psychedelic treatments.

Cybin's development programs have included CYB003, an investigational deuterated psilocybin analog being studied for major depressive disorder, and CYB004, an investigational deuterated DMT molecule being evaluated for generalized anxiety disorder and other mental health indications.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.